CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 8 enrolled
Drug / intervention
Probeneciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02243631
NCT02243631Early Ph 1Completed
CompareCT.gov

ANK-dependent ATP Efflux Causes Calcium Pyrophosphate Deposition in Cartilage

VA Office of Research and Development·interventional·Posted Sep 18, 2014·Updated Jul 26, 2022

In Brief

A Early Phase 1 clinical trial evaluating Probenecid for Calcium Pyrophosphate Deposition Disease. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCalcium Pyrophosphate Deposition Disease
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 18, 2014
Enrollment StartOct 15, 2014
Primary CompletionApr 8, 2021
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 11.8 years ago

Interventions

Probeneciddrug

Treatment